UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020968
Receipt number R000024191
Scientific Title The clinical study to explore the effects of DPP-4 inhibitors on responses of lipid
Date of disclosure of the study information 2016/02/11
Last modified on 2016/02/10 12:08:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The clinical study to explore the effects of DPP-4 inhibitors on responses of lipid

Acronym

The clinical study to explore the effects of DPP-4 inhibitors on responses of lipid

Scientific Title

The clinical study to explore the effects of DPP-4 inhibitors on responses of lipid

Scientific Title:Acronym

The clinical study to explore the effects of DPP-4 inhibitors on responses of lipid

Region

Japan


Condition

Condition

Type 2 Diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To explore the effects of anagliptin or sitagliptin on responses of lipid parameters in type 2 diabetic patients.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

small dense LDL and large LDL particles,
HDL2 and 3 particles,
Apoprotein, MDA-LDL,
cholesterol absorption marker, cholesterol biosynthesis marker

Key secondary outcomes

plasma glcose, central blood pressure
high-sensitivity CRP
U-LFABP
U-alb


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Anagliptin 100 mg twice a day for 6months

Interventions/Control_2

Sitagliptin 50 mg once a day for 6months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

1. Outpatients with type 2 diabetes (HbA1c:6.5-10%) who were attended to Showa University Hospital (Tokyo, Japan)
2.Patients who are 20-85 years old
3.Patients who themselves can voluntarily provide consent to participate in this study

Key exclusion criteria

1.Patients who are acute disease
2.Patients who are past history of hypersensitivity to anagliptin
3.Pregnant or woman of child-bearing potential
4.Patients who are stage5 of diabetic nephropathy
5.Patients who are judged as inappropriate for inclusion by phsicians

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshiyuki Hayashi

Organization

Showa University School of Medicine

Division name

Division of Diabetes and Endocrinology, Department of Internal Medicine

Zip code


Address

1-5-8 Hatanodai, Shinagawa-ku, Tokyo

TEL

03-3784-8000

Email

t-hayashi@med.showa-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Toshiyuki Hayashi

Organization

Showa University School of Medicine

Division name

Division of Diabetes and Endocrinology, Department of Internal Medicine

Zip code


Address

1-5-8 Hatanodai, Shinagawa-ku, Tokyo

TEL

03-3784-8000

Homepage URL


Email

t-hayashi@med.showa-u.ac.jp


Sponsor or person

Institute

Showa University School of Medicine, Division of Diabetes and Endocrinology, Department of Internal Medicine

Institute

Department

Personal name



Funding Source

Organization

SANWA KAGAKU KENKYUSHO CO.,LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

昭和大学病院


Other administrative information

Date of disclosure of the study information

2016 Year 02 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 02 Month 28 Day

Date of IRB


Anticipated trial start date

2014 Year 03 Month 01 Day

Last follow-up date

2015 Year 12 Month 31 Day

Date of closure to data entry

2015 Year 12 Month 31 Day

Date trial data considered complete

2016 Year 03 Month 31 Day

Date analysis concluded

2016 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 02 Month 10 Day

Last modified on

2016 Year 02 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024191


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name